What exactly did Jefferies do and when?

On March 03, 2026 at 10:51 AM Jefferies **reiterated a Buy** on Roivant Sciences Ltd. The note followed FDA acceptance of the brepocitinib NDA. The ROIV analyst rating did not include a new price target and the stock moved down **-1.1% ($-0.31)** on the update.

Did Jefferies change the ROIV price target?

No. Jefferies maintained its Buy stance but did not publish a revised ROIV price target in the March 03, 2026 note. The firm highlighted regulatory progress but left explicit valuation and target assumptions unchanged pending further data or commercial detail.

How should investors treat the maintained Buy from Jefferies?

A maintained Buy signals continued confidence in Roivant’s prospects while not increasing near-term upside. Investors should track FDA milestones, commercial planning, and cash runway. Meyka AI assigns ROIV a grade of B to reflect fundamentals and analyst consensus, but this is not financial advice.

Analyst Ratings

Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026

ByDanny Kontos March 4, 2026March 4, 2026

Jefferies reiterated a Buy on Roivant Sciences Ltd. (ROIV) on March 03, 2026, keeping its positive stance after the FDA accepted the brepocitinib NDA. The ROIV analyst rating note was issued at 10:51 AM ET and accompanies regulatory progress that Jefferies cites as a key catalyst. The firm left price guidance unspecified. Investors should note the stock moved -1.1% ($-0.31) on the news.